Candida auris infection

Development of reverse transcription loop-mediated isothermal amplification-based assay for rapid and specific detection of human fungal pathogen, Candida auris

mycolabadmin

Researchers developed a new rapid test called RT-LAMP to detect Candida auris, a dangerous multidrug-resistant fungus that causes hospital infections. The test works by changing color from pink to yellow when the fungus is present, making it easy to read without special equipment. It is more sensitive and specific than current methods, can be done quickly at a single temperature, and costs much less than existing tests, making it ideal for hospitals and clinics with limited resources.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species

mycolabadmin

Researchers tested a combination of an old antiparasitic drug called pyrvinium pamoate with common antifungal medications called azoles against dangerous drug-resistant fungal infections. While pyrvinium pamoate alone was not very effective, when combined with azoles it significantly improved the treatment of Candida auris infections. Tests in insect larvae showed that the combination improved survival rates better than using azoles alone, suggesting a promising new treatment approach for serious fungal infections.

Multi-omics Analysis of Experimentally Evolved Candida auris Isolates Reveals Modulation of Sterols, Sphingolipids, and Oxidative Stress in Acquired Amphotericin B Resistance

mycolabadmin

Researchers studied how the fungus Candida auris develops resistance to amphotericin B, an important antifungal drug. By evolving two laboratory strains of this fungus under drug pressure, they discovered two different ways the fungus can become resistant: one through stress management genes, the other through changes in its protective lipids. These findings help explain why some clinical infections with this dangerous fungus are so hard to treat.

HIV protease inhibitors restore amphotericin B activity against Candida

mycolabadmin

Researchers discovered that HIV protease inhibitors, medications commonly used to treat HIV, can significantly enhance the effectiveness of amphotericin B, a powerful antifungal drug. When combined, these medications work synergistically to kill the dangerous fungus Candida auris, reduce its ability to form protective biofilms, and lower infection levels. This finding suggests a promising new treatment strategy for multidrug-resistant fungal infections that currently pose a serious global health threat.

Brown locusts, Locustana pardalina, host fluconazole-resistant Candidozyma (Candida) auris, closely related to Clade III clinical strains

mycolabadmin

Scientists found that brown locusts in South Africa carry a dangerous yeast called Candida auris that is resistant to the antifungal drug fluconazole. This yeast is similar to strains that infect hospital patients and is highly adaptable, surviving extreme temperatures and salt levels found in locust guts. This discovery suggests that insects like locusts could play a role in spreading this emerging fungal pathogen in nature, which has important implications for understanding how dangerous microbes spread between animals and humans.

Characterizing antimicrobial activity of environmental Streptomyces spp. and oral bacterial and fungal isolates from Canis familiaris and Felis catus

mycolabadmin

Researchers collected bacteria and fungi from the mouths of pet dogs and cats, as well as environmental soil bacteria, to search for natural antimicrobial compounds. They found that some of these microorganisms produce substances that can kill harmful bacteria like E. coli and fungi like Candida albicans, especially when combined with existing antifungal medications. Notably, one environmental bacterium (Streptomyces) produced a compound that was even effective against fungal strains resistant to common antifungal drugs, suggesting promising new treatment possibilities.

Discovery of the antifungal compound ilicicolin K through genetic activation of the ilicicolin biosynthetic pathway in Trichoderma reesei

mycolabadmin

Scientists used genetic engineering to activate a dormant gene cluster in the fungus Trichoderma reesei, enabling it to produce the antifungal compound ilicicolin H in high quantities. During this process, they discovered a new related compound called ilicicolin K that shows even stronger antifungal properties. These compounds could potentially overcome limitations of current antifungal treatments, especially against drug-resistant fungi like Candida auris.

Caged-hypocrellin mediated photodynamic therapy induces chromatin remodeling and disrupts mitochondrial energy metabolism in multidrug-resistant Candida auris

mycolabadmin

Researchers developed a new photodynamic therapy treatment using a light-activated compound called COP1T-HA to fight drug-resistant Candida auris infections. The therapy works by reorganizing the fungal cell’s genetic material architecture and disrupting energy production in mitochondria, ultimately killing the fungal cells. This approach represents a novel strategy to overcome antibiotic resistance, as it targets multiple cellular processes rather than a single pathway that fungi can easily resist.

The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents

mycolabadmin

Researchers studied how an iron-chelating medication called deferiprone could improve the effectiveness of antifungal drugs against Candida auris, a dangerous drug-resistant fungus. They tested deferiprone combined with several common antifungal medications on different strains of the fungus from around the world. They found that deferiprone worked best when combined with echinocandin drugs, especially against certain regional variants of the fungus, potentially offering a new therapeutic approach for these difficult-to-treat infections.

Disease: Candida auris infection